
Personalis Inc (PSNL) Stock Forecast & Price Target
Personalis Inc (PSNL) Analyst Ratings
Bulls say
Personalis is a promising company in the growing field of personalized cancer therapies, as demonstrated by the strong demand for its sequencing and data analysis services. With limited competition in the MRD market and the potential for further growth in both its biopharma and clinical diagnostic businesses, we believe Personalis is positioned for success. Despite recent takeover speculation, we remain confident that Personalis will continue to thrive and maintain a strong financial position, potentially leading to further expansion in the future.
Bears say
Personalis is a young company with limited revenue sources and a high reliance on biopharma partnerships, which could significantly impact its growth if these partnerships do not materialize. The company is also facing competition from other genomic sequencing companies and may struggle to differentiate itself in the market. Additionally, there is uncertainty around its future financials, with a wide range of projections and a high risk of budget and ordering volatility from its biopharma customers.
This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.
Personalis Inc (PSNL) Analyst Forecast & Price Prediction
Start investing in Personalis Inc (PSNL)
Order type
Buy in
Order amount
Est. shares
0 shares